Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea will conduct R&D work related to Advantage’s portfolio based around Klotho, ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

The annual Fierce 50 Gala is set to shine a spotlight on the life sciences industry's most transformative leaders, ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral ...

After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...